GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing.


Journal

Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660

Informations de publication

Date de publication:
12 07 2021
Historique:
received: 21 01 2021
accepted: 30 06 2021
entrez: 13 7 2021
pubmed: 14 7 2021
medline: 22 1 2022
Statut: epublish

Résumé

GRIDSS2 is the first structural variant caller to explicitly report single breakends-breakpoints in which only one side can be unambiguously determined. By treating single breakends as a fundamental genomic rearrangement signal on par with breakpoints, GRIDSS2 can explain 47% of somatic centromere copy number changes using single breakends to non-centromere sequence. On a cohort of 3782 deeply sequenced metastatic cancers, GRIDSS2 achieves an unprecedented 3.1% false negative rate and 3.3% false discovery rate and identifies a novel 32-100 bp duplication signature. GRIDSS2 simplifies complex rearrangement interpretation through phasing of structural variants with 16% of somatic calls phasable using paired-end sequencing.

Identifiants

pubmed: 34253237
doi: 10.1186/s13059-021-02423-x
pii: 10.1186/s13059-021-02423-x
pmc: PMC8274009
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

202

Informations de copyright

© 2021. The Author(s).

Références

Genome Biol. 2012;13(3):R22
pubmed: 22452995
Nature. 2020 Feb;578(7793):112-121
pubmed: 32025012
Viruses. 2016 Mar 01;8(3):66
pubmed: 26938550
Bioinformatics. 2012 Jul 15;28(14):1919-20
pubmed: 22576172
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Nat Commun. 2019 Jul 19;10(1):3240
pubmed: 31324872
Genome Res. 2002 Apr;12(4):656-64
pubmed: 11932250
Gigascience. 2015 Dec 24;4:64
pubmed: 26705468
Genome Res. 2018 Apr;28(4):581-591
pubmed: 29535149
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Nature. 2021 May;593(7857):101-107
pubmed: 33828295
Bioinformatics. 2012 Sep 15;28(18):i333-i339
pubmed: 22962449
Bioinformatics. 2014 Apr 15;30(8):1064-1072
pubmed: 24389656
Nat Methods. 2011 Jun 12;8(8):652-4
pubmed: 21666668
BMC Bioinformatics. 2019 Dec 17;20(Suppl 20):641
pubmed: 31842730
Bioinformatics. 2021 May 11;:
pubmed: 33973999
Nat Biotechnol. 2014 Nov;32(11):1106-12
pubmed: 25344728
Bioinformatics. 2016 Apr 15;32(8):1220-2
pubmed: 26647377
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Nat Commun. 2017 Nov 6;8(1):1326
pubmed: 29109544
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Genome Res. 2017 Dec;27(12):2050-2060
pubmed: 29097403
Bioinformatics. 2011 Aug 1;27(15):2156-8
pubmed: 21653522
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Methods Mol Biol. 2018;1833:129-141
pubmed: 30039369
Bioinformatics. 2009 Nov 1;25(21):2865-71
pubmed: 19561018
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Science. 2014 Aug 01;345(6196):1251343
pubmed: 25082706
Genome Biol. 2019 Jun 3;20(1):117
pubmed: 31159850
PLoS One. 2013 Dec 04;8(12):e82138
pubmed: 24324759
Curr Protoc Bioinformatics. 2014;45:15.6.1-11
pubmed: 25152801

Auteurs

Daniel L Cameron (DL)

Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. cameron.d@wehi.edu.au.
Department of Medical Biology, University of Melbourne, Melbourne, Australia. cameron.d@wehi.edu.au.
Hartwig Medical Foundation Australia, Sydney, Australia. cameron.d@wehi.edu.au.

Jonathan Baber (J)

Hartwig Medical Foundation Australia, Sydney, Australia.
Hartwig Medical Foundation, Science Park 408, Amsterdam, The Netherlands.

Charles Shale (C)

Hartwig Medical Foundation Australia, Sydney, Australia.
Hartwig Medical Foundation, Science Park 408, Amsterdam, The Netherlands.

Jose Espejo Valle-Inclan (JE)

Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

Nicolle Besselink (N)

Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

Arne van Hoeck (A)

Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

Roel Janssen (R)

Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

Edwin Cuppen (E)

Hartwig Medical Foundation, Science Park 408, Amsterdam, The Netherlands.
Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.

Peter Priestley (P)

Hartwig Medical Foundation Australia, Sydney, Australia.
Hartwig Medical Foundation, Science Park 408, Amsterdam, The Netherlands.

Anthony T Papenfuss (AT)

Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. papenfuss@wehi.edu.au.
Department of Medical Biology, University of Melbourne, Melbourne, Australia. papenfuss@wehi.edu.au.
Peter MacCallum Cancer Centre, Melbourne, Australia. papenfuss@wehi.edu.au.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. papenfuss@wehi.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH